Management ChangeApr 13, 2026, 08:41 AM
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
AI Summary
ALX Oncology Holdings Inc. announced the appointment of Jeff Knight as its new Chief Development and Operating Officer, effective April 13, 2026. Knight brings a wealth of experience from various biopharmaceutical companies, including Crinetics Pharmaceuticals, Poseida Therapeutics, and Amgen. His background in development operations, portfolio management, and corporate operations is expected to strengthen ALX Oncology's leadership team.
Key Highlights
- ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer.
- Knight previously served as Chief Development and Operating Officer at Crinetics Pharmaceuticals from September 2021 to April 2026.
- He held senior roles at Poseida Therapeutics, Halozyme Therapeutics, Amgen, and Onyx Pharmaceuticals.
- Knight brings extensive experience in portfolio management, corporate operations, and development operations.
Price Impact
More from ALXO